Lexicon Pharmaceuticals (NASDAQ:LXRX) (NASDAQ:LXRX) is a biopharmaceutical company dedicated to discovering and developing novel pharmaceutical products that address significant unmet medical needs. Leveraging its proprietary gene knockout platform, the company identifies targets essential to disease processes and develops small-molecule inhibitors to modulate those targets. Lexicon’s research model emphasizes rapid target validation in genetically engineered animal models, accelerating the transition from discovery to clinical development.
The company’s first approved product, XERMELO® (telotristat ethyl), is indicated for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy. Building on this success, Lexicon is advancing a diversified pipeline of investigational therapies focused on metabolic diseases, gastrointestinal disorders, and chronic pain. Key clinical-stage assets include investigational agents for type 1 diabetes-associated hypoglycemia, diabetic peripheral neuropathy, and other rare disease indications.
Founded in 1995 and headquartered in The Woodlands, Texas, Lexicon operates research and development facilities in the United States and maintains collaborative partnerships in Europe and Asia. The company’s scientific team comprises experts in molecular biology, medicinal chemistry, translational pharmacology, and clinical medicine. Through strategic alliances with academic institutions and industry partners, Lexicon expands its global reach and accelerates the development of innovative therapies.
Leadership at Lexicon is focused on delivering value through disciplined pipeline management and efficient clinical execution. Chief Executive Officer Jack W. Klempner brings extensive experience in drug development and commercialization, having held senior roles at several biotechnology companies. The management team’s expertise in both early-stage research and late-stage clinical operations underscores Lexicon’s commitment to translating genetic insights into life-changing treatments for patients worldwide.
